Immune checkpoint blockade (ICB) activates antitumor cytotoxic T-cell responses and improves the efficiency of cancer therapy by blocking regulatory receptors expressed on immune or tumor cells, with PD-1/PD-L1 and CTLA-4 being the key targets for immune checkpoint blockade therapy [191]. This evidence concerns the gene PDCD1 and neoplasm.